drugset / Trial / NCT05472467
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study evaluated the effectiveness and safety of Camrelizumab combination with SBRT and concurrent chemotherapy treated stage IV oligometastatic non-small cell lung cancer
Timeline
- Start
- 2021-12-21
- Primary completion
- 2023-12-20
- Completion
- 2023-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | 4 unknown | — |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Background | Docetaxel | Small molecule | 60 mg/m2 | — |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | — |